Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC trimmed its position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Rating) by 27.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,053 shares of the biopharmaceutical company’s stock after selling 9,536 shares during the period. SG Americas Securities LLC’s holdings in Lexicon Pharmaceuticals were worth $48,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of LXRX. ProShare Advisors LLC boosted its holdings in shares of Lexicon Pharmaceuticals by 24.2% in the 3rd quarter. ProShare Advisors LLC now owns 24,625 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 4,793 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of Lexicon Pharmaceuticals by 76.8% in the 3rd quarter. Victory Capital Management Inc. now owns 20,433 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 8,873 shares in the last quarter. LPL Financial LLC grew its stake in Lexicon Pharmaceuticals by 88.2% during the second quarter. LPL Financial LLC now owns 20,700 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 9,700 shares during the period. Bank of Montreal Can acquired a new stake in shares of Lexicon Pharmaceuticals in the first quarter worth $26,000. Finally, Northern Trust Corp raised its stake in shares of Lexicon Pharmaceuticals by 1.8% in the 2nd quarter. Northern Trust Corp now owns 672,463 shares of the biopharmaceutical company’s stock valued at $1,252,000 after acquiring an additional 12,057 shares during the period.

Lexicon Pharmaceuticals Trading Down 1.4 %

NASDAQ LXRX opened at $2.89 on Friday. The company’s fifty day moving average price is $2.53 and its two-hundred day moving average price is $2.31. The company has a market capitalization of $547.83 million, a price-to-earnings ratio of -4.66 and a beta of 1.33. Lexicon Pharmaceuticals, Inc. has a 12 month low of $1.31 and a 12 month high of $3.79. The company has a debt-to-equity ratio of 0.55, a current ratio of 5.38 and a quick ratio of 5.38.

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Rating) last posted its quarterly earnings results on Thursday, March 2nd. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The firm had revenue of $0.03 million during the quarter. Lexicon Pharmaceuticals had a negative return on equity of 105.14% and a negative net margin of 87,620.63%. As a group, research analysts predict that Lexicon Pharmaceuticals, Inc. will post -0.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on LXRX. StockNews.com assumed coverage on Lexicon Pharmaceuticals in a research report on Thursday. They issued a “sell” rating on the stock. Jefferies Financial Group assumed coverage on shares of Lexicon Pharmaceuticals in a research report on Tuesday, March 7th. They set a “hold” rating and a $3.00 target price on the stock.

About Lexicon Pharmaceuticals

(Get Rating)

Lexicon Pharmaceuticals, Inc engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes.